Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer.

[1]  G. Creemers,et al.  Capecitabine-Associated Terminal Ileitis , 2018, Case Reports in Oncology.

[2]  C. Punt,et al.  Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm. , 2017, European journal of cancer.

[3]  C. Punt,et al.  Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  C. Punt,et al.  Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group. , 2017, European journal of cancer.

[5]  C. Punt,et al.  Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in western cancer patients , 2017, Acta oncologica.

[6]  E. Kuipers,et al.  Prospective Dutch colorectal cancer cohort: an infrastructure for long-term observational, prognostic, predictive and (randomized) intervention research , 2016, Acta oncologica.

[7]  J. Kwakman,et al.  Oral drugs in the treatment of metastatic colorectal cancer , 2016, Expert opinion on pharmacotherapy.

[8]  M. Tanahashi,et al.  Distinctive impact of pre-existing interstitial lung disease on the risk of chemotherapy-related lung injury in patients with lung cancer , 2016, Cancer Chemotherapy and Pharmacology.

[9]  D. Shin,et al.  Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. , 2013, The Lancet. Oncology.

[10]  J. Glaholm,et al.  Pulmonary Toxicity with Oxaliplatin and Capecitabine/5-Fluorouracil Chemotherapy: A Case Report and Review of the Literature , 2011, Oncology Research and Treatment.

[11]  K. Kiura,et al.  An oral fluoropyrimidine agent S-1 induced interstitial lung disease: A case report. , 2011, World journal of clinical oncology.

[12]  Yoshiaki Tanaka,et al.  Interstitial lung disease during chemotherapy combined with oxaliplatin and/or bevacizumab in advanced colorectal cancer patients. , 2011, Japanese journal of clinical oncology.

[13]  M. Stockler,et al.  Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Johnston,et al.  An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  S. Abid,et al.  Radiation-induced and chemotherapy-induced pulmonary injury , 2001, Current opinion in oncology.

[16]  M. Fukushima,et al.  Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. , 1996, Anti-cancer drugs.

[17]  B. Reigner,et al.  Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients , 2000, Cancer Chemotherapy and Pharmacology.